Abstract
The molecular mechanisms that underlie the relationship between adiposity and poorer breast cancer outcomes are not well understood but might be explained partly by the biological effects of the adipokines, adiponectin (ADIPOQ) and leptin (LEP), which are secreted by adipocytes, and their respective receptors (ADIPOR1, ADIPOR2, LEPR). Prior work has shown that circulating ADIPOQ and LEP are not well correlated with levels within histologically normal tissues, underscoring the need for research to characterize tissue-based and tumor-based adipokine and adipokine receptor expression and their relationship with cancer outcomes. There is a dearth of epidemiologic data on the relationship between body fatness and protein and gene expression of the adipokines and adipokine receptors. Furthermore, the relationship between protein and gene expression of the adipokines and adipokine receptors with cancer is also not well understood. This presentation will discuss recent findings from the Women’s Circle of Health Study supporting an association between increased body fatness – beyond body mass index (BMI) – and expression of the adipokines and adipokine receptors and between protein and gene expression of these markers with more aggressive breast tumor features. Clarification of the impact of adiposity-related adipokine and adipokine receptor expression in the breast tumor microenvironment on long-term breast cancer outcomes is a critical next step.
Citation Format: Adana A.M. Llanos. Adipokine and adipokine receptor expression in breast tumors: Associations with greater body fatness and more aggressive clinicopathologic features [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA047.
RSS Feeds